CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.
  
  LEARNING OBJECTIVES

  • Appreciate the prevalence and relevance of HER2 amplification/overexpression in various gynecologic cancers, and consider the implications for biomarker assessment and clinical management.
  • Evaluate published research findings with established HER2-targeted therapies for patients with HER2-positive gynecologic cancers, and assess the current role of various agents and regimens.
  • Recall available data with novel HER2-targeted antibody-drug conjugates for HER2-positive ovarian, endometrial and cervical cancers, and optimally integrate these agents into the care of appropriately selected patients.
  • Appraise the side effects associated with various HER2-directed therapies commonly employed in the care of patients with gynecologic cancers, and use this information to develop supportive therapeutic plans for those undergoing treatment with these agents or regimens.
  • Recall the design of ongoing clinical trials evaluating novel HER2-directed agents and strategies for advanced HER2-positive gynecologic cancers, and counsel appropriately selected patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Interview: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Interview: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 2.25 (audio) and 1.75 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINOUS CERTIFICATION (CC)
  Successful completion of these CME activities, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
  
  Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology. 
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/SGO25HER2PosGyn/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/SGO25HER2PosGyn/Video.
  
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/SGO25HER2PosGyn/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/SGO25HER2PosGyn.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of these activities. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Kathleen N Moore, MD, MS
  Deputy Director
  Virginia Kerley Cade Chair in Developmental Therapeutics
  Co-Director, Cancer Therapeutics Program
  Stephenson Cancer Center at the University of Oklahoma HSC
  Associate Director, GOG Partners
  Board of Directors, GOG Foundation
  Board of Directors, ASCO
  Oklahoma City, Oklahoma
  
  Advisory Committees: Aadi Bioscience, AbbVie Inc, AstraZeneca Pharmaceuticals LP, BioNTech SE, Blueprint Medicines, Caris Life Sciences, Corcept Therapeutics, Daiichi Sankyo Inc, Duality Biologics, Eisai Inc, Genentech, a member of the Roche Group, GSK, ImmunoGen Inc, Janssen Biotech Inc, Lilly, Merck, Mersana Therapeutics Inc, Novartis, Regeneron Pharmaceuticals Inc, Schrödinger, Takeda Pharmaceuticals USA Inc, Verastem Inc, Zentalis Pharmaceuticals, Zymeworks Inc; Contracted Research: Allarity Therapeutics, Daiichi Sankyo Inc, GSK, ImmunoGen Inc, Schrödinger, Verastem Inc; Data and Safety Monitoring Boards/Committees: Bicycle Therapeutics.
  
  Alessandro D Santin, MD
  Professor
  Department of Obstetrics and Gynecology
  Co-Chief, Gynecologic Oncology
  Yale University School of Medicine
  New Haven, Connecticut
  
  Advisory Committees: Daiichi Sankyo Inc, Eisai Inc, Gilead Sciences Inc, Merck, Pfizer Inc, R-Pharm US; Contracted Research: Boehringer Ingelheim Pharmaceuticals Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Merck, R-Pharm US, Synthon, Tesaro, A GSK Company, Verastem Inc.
  
  MODERATOR
  David M O'Malley, MD
  Director and Professor
  Division of Gynecologic Oncology in Obstetrics and Gynecology
  John G Boutselis Chair in Gynecologic Oncology
  The Ohio State University and The James Comprehensive Cancer Center
  Columbus, Ohio
  
  Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics, Duality Biologics, Genmab US Inc, GSK, Merck, MSD, Regeneron Pharmaceuticals Inc, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Verastem Inc; Contracted Research: AbbVie Inc, Adaptimmune, Advaxis Inc, Agenus Inc, Alkermes, Aravive Inc, Arcus Biosciences, Arquer Diagnostics, AstraZeneca Pharmaceuticals LP, Atossa Therapeutics, BeiGene Ltd, Bristol Myers Squibb, Cardiff Oncology, Celcuity, Clovis Oncology, Corcept Therapeutics, Deciphera Pharmaceuticals Inc, Duality Biologics, Eisai Inc, Elevar Therapeutics, EMD Serono Inc, Exelixis Inc, Genelux Corporation, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Imvax Inc, Incyte Corporation, InterVenn Biosciences, InxMed, Iovance Biotherapeutics, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Laekna Therapeutics, Leap Therapeutics Inc, Luzsana Biotechnology, Merck, Mersana Therapeutics Inc, MSD, Myriad Genetic Laboratories Inc, Novartis, Novocure Inc, Onconova Therapeutics Inc, OncoQuest Inc, Pfizer Inc, Predictive Oncology Inc, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Replimune, Roche Laboratories Inc, R-Pharm US, Rubius Therapeutics, Seagen Inc, Sorrento Therapeutics, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Tarveda Therapeutics, Tesaro, A GSK Company, Toray Industries Inc, Trillium Therapeutics Inc, Umoja Biopharma, VBL Therapeutics, Verastem Inc, Vincerx Pharma, Xencor, Zentalis Pharmaceuticals; Nonrelevant Financial Relationships: Amarex Clinical Research, GOG Foundation, Ludwig Institute for Cancer Research Ltd, National Cancer Institute, NRG Oncology, RTOG Foundation, SWOG.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.
  
  Release date: April 2025
  Expiration date: April 2026
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.